Auro Laboratories Ltd
Incorporated in 1989, Auro Laboratories Limited is into the manufacturing of Active Pharmaceutical Ingredients (APIs), specializing in Diabetes therapy. The company also also undertakes Toll/Custom Manufacturing for API's and Intermediates on contract basis.
Key API Products of Auro Labs are:[1]
- Metformin Hydrochloride
- Chlorzoxzone
- Chlorphenamine Maleate
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Dividend Payout % |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Equity Capital |
Reserves |
Preference Capital |
Total Liabilities |
CWIP |
Investments |
Total Assets |
Cash Flows
Figures in Rs. Crores
Net Cash Flow |
Ratios
Figures in Rs. Crores
Debtor Days |
Inventory Days |
Days Payable |
Cash Conversion Cycle |
Working Capital Days |
ROCE % |
Documents
Announcements
- Corrigendum To Audited Financial Results For The Quarter And Financial Year Ended March 31, 2024 2d
- Corrigendum To Audited Financial Results For The Quarter And Year Ended March 31, 2024 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Jun
- Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Jun
- Intimation Of 35Th Annual General Meeting To Be Held On Friday, June 28, 2024 6 Jun
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:[1]
a) Active Pharmaceutical Ingredients:
Anti-Diabetics, Anti-Histamines, Muscle Relaxants, Diuretics, Anti Fungal, Anti Ulcer, Anti Fungal, Anti Ulcer, Iodine Supplement, Iron Supplement, Anti Malaria, Analgesics, Antacids, Anti Inflammatory, Specialty Chemicals, etc.
b) Intermediates: [2]
Few Intermediates which are used in APIs are Glibenclamide, Ketoconazol, Sildenafil Citrate, and Citalopram